A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven, advanced epithelial ovarian cancer.
• Histologic confirmation by Pathology Department, NIH, required.
• Recurrent disease after paclitaxel and either cisplatin or carboplatin. Combination platinum/paclitaxel acceptable.
• Bidimensionally measurable disease on physical exam, radiographs, or peritoneoscopy. Repeat peritoneoscopy after 8 courses of therapy required if documentation of disease was solely by peritoneoscopy.
• Laparotomy not required.
• No CNS metastasis.
• No borderline or mixed histology.
• PRIOR/CONCURRENT THERAPY:
• See Disease Characteristics.
• More than 4 weeks since any prior therapy and recovered.
• No prior camptothecin analogue-based chemotherapy.
• No prior radiotherapy except intraperitoneal 32-P.
• PATIENT CHARACTERISTICS:
• Age: 18 and over.
• Performance status: ECOG 0-2.
• Hematopoietic:
• WBC greater than 3,000.
• AGC greater than 1,500.
• Platelets at least 100,000.
• Hemoglobin greater than 9 g/dL OR;
• Hematocrit greater than 27 g/dL.
• Hepatic:
• Bilirubin no greater than 1.5 mg/dL.
• Serum transaminases no greater than 2 times normal.
• Renal:
• 24-hour creatinine clearance greater than 45 mL/min (documented by NCI investigator or primary care physician).
• Cardiovascular:
• No myocardial infarction within 12 months.
• No active congestive heart failure.
• No heart block.
• No arrhythmia requiring medication.
• OTHER:
• No active uncontrolled infection.
• No known HIV positivity.
• No second malignancy currently under treatment except: Local basal cell carcinoma of the skin, Cervical carcinoma in situ, Other malignancies (e.g., stage I breast cancer) eligible at the discretion of the principal or associate investigators.
• No pregnant women.